249 related articles for article (PubMed ID: 33315499)
21. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
22. Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Vlaming H; McLean CM; Korthout T; Alemdehy MF; Hendriks S; Lancini C; Palit S; Klarenbeek S; Kwesi-Maliepaard EM; Molenaar TM; Hoekman L; Schmidlin TT; Altelaar AM; van Welsem T; Dannenberg JH; Jacobs H; van Leeuwen F
EMBO J; 2019 Jul; 38(14):e101564. PubMed ID: 31304633
[TBL] [Abstract][Full Text] [Related]
23. The Role of DOT1L in Normal and Malignant Hematopoiesis.
Arnold O; Barbosa K; Deshpande AJ; Zhu N
Front Cell Dev Biol; 2022; 10():917125. PubMed ID: 35712672
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.
Zhang X; Liu D; Li M; Cao C; Wan D; Xi B; Li W; Tan J; Wang J; Wu Z; Ma D; Gao Q
J Hematol Oncol; 2017 Jan; 10(1):29. PubMed ID: 28114995
[TBL] [Abstract][Full Text] [Related]
25. Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-β production by mediating H3K79me2/3 methylation in macrophages.
Chen X; Liu X; Zhang Y; Huai W; Zhou Q; Xu S; Chen X; Li N; Cao X
Cell Mol Immunol; 2020 Jan; 17(1):76-84. PubMed ID: 30275539
[TBL] [Abstract][Full Text] [Related]
26. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
[TBL] [Abstract][Full Text] [Related]
27. Sirtuin 1 functionally and physically interacts with disruptor of telomeric silencing-1 to regulate alpha-ENaC transcription in collecting duct.
Zhang D; Li S; Cruz P; Kone BC
J Biol Chem; 2009 Jul; 284(31):20917-26. PubMed ID: 19491102
[TBL] [Abstract][Full Text] [Related]
28. DOT1L regulates dystrophin expression and is critical for cardiac function.
Nguyen AT; Xiao B; Neppl RL; Kallin EM; Li J; Chen T; Wang DZ; Xiao X; Zhang Y
Genes Dev; 2011 Feb; 25(3):263-74. PubMed ID: 21289070
[TBL] [Abstract][Full Text] [Related]
29. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
30. DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiation.
Cattaneo P; Kunderfranco P; Greco C; Guffanti A; Stirparo GG; Rusconi F; Rizzi R; Di Pasquale E; Locatelli SL; Latronico MV; Bearzi C; Papait R; Condorelli G
Cell Death Differ; 2016 Apr; 23(4):555-64. PubMed ID: 25526092
[TBL] [Abstract][Full Text] [Related]
31. Histone signature of metanephric mesenchyme cell lines.
McLaughlin N; Yao X; Li Y; Saifudeen Z; El-Dahr SS
Epigenetics; 2013 Sep; 8(9):970-8. PubMed ID: 23867747
[TBL] [Abstract][Full Text] [Related]
32. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
33. Dot1l deficiency leads to increased intercalated cells and upregulation of V-ATPase B1 in mice.
Xiao Z; Chen L; Zhou Q; Zhang W
Exp Cell Res; 2016 Jun; 344(2):167-75. PubMed ID: 26404731
[TBL] [Abstract][Full Text] [Related]
34. Mesenchyme-specific loss of Dot1L histone methyltransferase leads to skeletal dysplasia phenotype in mice.
Sutter PA; Karki S; Crawley I; Singh V; Bernt KM; Rowe DW; Crocker SJ; Bayarsaihan D; Guzzo RM
Bone; 2021 Jan; 142():115677. PubMed ID: 33022452
[TBL] [Abstract][Full Text] [Related]
35. DOT1L Regulates Thermogenic Adipocyte Differentiation and Function via Modulating H3K79 Methylation.
Shuai L; Li BH; Jiang HW; Yang L; Li J; Li JY
Diabetes; 2021 Jun; 70(6):1317-1333. PubMed ID: 33795413
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic priming by Dot1l in lymphatic endothelial progenitors ensures normal lymphatic development and function.
Yoo H; Lee YJ; Park C; Son D; Choi DY; Park JH; Choi HJ; La HW; Choi YJ; Moon EH; Saur D; Chung HM; Song H; Do JT; Jang H; Lee DR; Park C; Lee OH; Cho SG; Hong SH; Kong G; Kim JH; Choi Y; Hong K
Cell Death Dis; 2020 Jan; 11(1):14. PubMed ID: 31908356
[TBL] [Abstract][Full Text] [Related]
37. A charge-based interaction between histone H4 and Dot1 is required for H3K79 methylation and telomere silencing: identification of a new trans-histone pathway.
Fingerman IM; Li HC; Briggs SD
Genes Dev; 2007 Aug; 21(16):2018-29. PubMed ID: 17675446
[TBL] [Abstract][Full Text] [Related]
38. CREB trans-activation of disruptor of telomeric silencing-1 mediates forskolin inhibition of CTGF transcription in mesangial cells.
Yu Z; Kong Q; Kone BC
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F617-24. PubMed ID: 20053791
[TBL] [Abstract][Full Text] [Related]
39. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.
Feng Q; Wang H; Ng HH; Erdjument-Bromage H; Tempst P; Struhl K; Zhang Y
Curr Biol; 2002 Jun; 12(12):1052-8. PubMed ID: 12123582
[TBL] [Abstract][Full Text] [Related]
40. The emerging roles of DOT1L in leukemia and normal development.
McLean CM; Karemaker ID; van Leeuwen F
Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
